WeVote
Log In

Bill

Bill

H 4367

An Act relative to newborn screenings for congenital cytomegalovirus

194th Legislature (2025-2026) Introduced by Marjorie Decker and 21 co-sponsors

Bill H 4367 mandates universal screening for congenital cytomegalovirus in Massachusetts newborns, ensuring early detection and education for parents to improve health outcomes.

New draft substituted, see H5441
0
WeVote Research Nonpartisan
Bill Summary · H 4367

Summary of Bill H 4367: An Act Relative to Newborn Screenings for Congenital Cytomegalovirus

Purpose and Intent

Bill H 4367 aims to establish a comprehensive screening program for congenital cytomegalovirus (cCMV) in newborns across the Commonwealth of Massachusetts. The bill seeks to enhance public awareness and ensure early detection of cCMV, which can lead to serious health issues if not identified promptly.

Key Provisions

The bill introduces several significant changes to Chapter 111 of the General Laws:

1. Public Information Program

  • The Department of Public Health will create and maintain a public information program about cCMV.
  • Healthcare providers, including hospitals and birthing facilities, must provide expectant and new parents with educational materials about cCMV at the earliest prenatal appointment or during a preconception visit.

2. Required Newborn Screening

  • Universal cCMV Screening: All newborns will be screened for cCMV using a saliva or urine PCR test within 21 days of birth.
  • If a newborn tests positive, a confirmatory urine PCR test will be required.
  • Screening is mandatory unless the parent or guardian objects for sincerely held religious beliefs.

3. Implementation Timeline

  • A pilot program for universal cCMV screening will be initiated in the first year after the bill's passage.
  • Full implementation of the screening program is expected to begin in the second year.
  • Hospitals and birthing facilities must adopt screening protocols by January 1, 2028.

4. Coverage and Reporting

  • The costs of cCMV screening will be covered by all health insurers, with exceptions for certain supplemental policies.
  • If no third-party payer is available, the Commonwealth will cover the costs.
  • Hospitals must report annually to the Department on the number of tests administered and their outcomes.

Who Would Be Affected

  • Newborns: All liveborn infants in Massachusetts will be screened for cCMV.
  • Parents and Guardians: They will receive vital information about cCMV and its implications for their newborns.
  • Healthcare Providers: Hospitals, birthing facilities, and healthcare professionals involved in prenatal and postnatal care will be required to implement new protocols and provide educational materials.

Procedural Aspects

  • The bill was introduced on May 22, 2025, and has undergone several legislative actions, including referrals to committees and a scheduled hearing on November 3, 2025.
  • The bill is sponsored by a group of legislators led by Sally P. Kerans and includes multiple cosponsors.

Conclusion

Bill H 4367 represents a proactive approach to addressing congenital cytomegalovirus in Massachusetts, emphasizing early detection and education to improve health outcomes for newborns. By mandating screenings and providing necessary resources, the bill aims to mitigate the risks associated with cCMV infections.

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.